Clone:
1A1
Type of antibody:
Primary antibodies
Isotype:
rat IgG2aκ
Applications:
FC
Alternative names:
TNFRSF13B, CVID, CVID2, IGAD2, RYZN, TACI, TNFRSF14B

Specifications for CD267 (TACI) Antibody, anti-human

Overview

Clone 1A1 recognizes human CD267, a 32 kDa type III transmembrane protein belonging to the TNF receptor superfamily. CD267 as receptor binds to BAFF and APRIL and plays an important role in the stimulation of B and T cell–function and in the regulation of humoral immunity. CD267 expression is found in CD27
+
memory B cells, tonsillar and bone marrow plasma cells, in a subpopulation of activated CD27
, non-GC cells, and in a small subset of naive blood and tonsil B cells. CD267 is also expressed on many lymphomas such as multiple myeloma and Hodgkin and non-Hodgkin lymphomas. Mutations in CD267 are often associated with common variable immunodeficiency in humans. Signaling via CD267 leads to activation of the transcription factors NFAT, AP1, and NF-κB.

Alternative names

TNFRSF13B, CVID, CVID2, IGAD2, RYZN, TACI, TNFRSF14B

Detailed product information

Technical specifications

Clone1A1
Clonalitymonoclonal
Isotyperat IgG2aκ
Isotype controlIsotype Control Antibody, rat IgG2a
Hostrat
Type of antibodyPrimary antibodies
Specieshuman
AntigenCD267 (TACI)
Alternative names of antigenTNFRSF13B, CVID, CVID2, IGAD2, RYZN, TACI, TNFRSF14B
Molecular mass of antigen [kDa]32
Distribution of antigenB cells
Entrez Gene ID23495
RRIDAB_2656771, AB_2656772, AB_2656773, AB_2656770

References for CD267 (TACI) Antibody, anti-human

Publications

  1. Salzer, U. et al. (2005) Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans. Nat. Genet. 37(8): 820-828
  2. Mackay, F. et al. (2008) TACI, an enigmatic BAFF/APRIL receptor, with new unappreciated biochemical and biological properties. Cytokine Growth Factor Rev. 19(3–4): 263-276

Related products for
CD267 (TACI) Antibody, anti-human

2 products available

Seems like you are coming from USA!
Do you want to visit our website in your country?